Medifarm

What Medifarm does

Medifarm S.r.l. is an Italian privately-held pharmaceutical company that specializes in parallel importation of branded medications into Italy, operating as the Italian entity of a European multinational pharmaceutical group with affiliated offices in France, the United Kingdom, Spain, Portugal, Germany, and the Netherlands. Founded in 2000 and headquartered in Rome, the company holds over 200 parallel import licenses (Autorizzazione di Importazione Parallela, or AIP) issued by AIFA (Agenzia Italiana del Farmaco), allowing it to source brand-name medications from other EU member states — where they are sold at lower prices than in Italy — and relabel and repackage them for sale on the Italian market. Products are sourced from a broad set of European geographies including France, the UK, Germany, Spain, Portugal, the Netherlands, Poland, Belgium, Hungary, Greece, and Austria, and span therapeutic categories such as analgesics, antacids, dermatologicals, gastrointestinal medications, antihistamines, and ophthalmic preparations.

Medifarm operates a B2B sales-led distribution model exclusively targeting Italian pharmacies, currently serving more than 2,000 customers nationwide. Order management is handled through QUICKO, a proprietary online platform (medifarm.quicko.eu) with reserved access for registered pharmacies, offering monthly billing, real-time product availability, PDF order downloads, and annual sales volume controls. The company supplements this with a WhatsApp Broadcast service for promotional offers and participates in major European pharmaceutical trade shows including Cosmofarma, Pharmagora, Expopharm, Infarma, and The Pharmacy Show. Secondary repackaging is performed by licensed facilities under the supervision of Bezirksregierung Düsseldorf (Germany) and the Health and Youth Care Inspectorate — Pharmaceutical Affairs (Netherlands), with pharmacovigilance services provided in-house and routed to AIFA and parent-company authorities. Revenue is generated through product resale margin on each transaction, with pricing information not publicly disclosed and no other revenue streams identified.

Name

Medifarm

Legal name

Medifarm S.r.l.

Website

https://medifarmitalia.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

Medifarm S.r.l. is an Italian B2B pharmaceutical company specializing in parallel importation of branded medications from EU member states, distributing over 200 AIFA-licensed products to more than 2,000 pharmacy clients across Italy via its QUICKO online ordering platform.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Parallel Import/Export & Secondary Market Pharmaceutical Wholesalers (HLAIAJAK)

akta.pro secondary industry

Import/Export Controls, Supply Chain Integrity & Anti-Counterfeiting (HLAJADAJ)

Keywords

• Parallel pharmaceutical imports
• Branded medication distribution
• AIFA authorized drugs
• Pharmacy supply services
• Cross-border pharmaceuticals

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Parallel Imported Pharmaceuticals: Medifarm generates revenue through the sale of parallel-imported branded medications sourced from other EU countries (France, Great Britain, Spain, Portugal, Germany, Netherlands) at lower prices than the Italian market, resold to pharmacies across Italy. The business model is based on price differentials between EU member states.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Medifarm parallel imports branded pharmaceutical products from other European Union member states, obtains AIFA parallel-import (AIP) authorization, relabels and repackages them for the Italian market, and distributes them to pharmacies nationwide. The portfolio spans over 200 parallel-import licenses across therapeutic categories including analgesics, antacids, anti-inflammatory drugs, dermatological preparations, gastrointestinal medications, antihistamines, eye-care products, and cardiovascular agents, sourced from countries including France, the UK, Germany, Spain, Portugal, the Netherlands, Poland, Belgium, Hungary, Austria, and Greece.

Product overview

Medifarm S.r.l. is a pharmaceutical company specializing in parallel importation of branded medications from other EU countries into Italy. The company's core offering consists of over 200 licensed parallel-imported pharmaceutical products distributed to more than 2,000 pharmacy clients throughout Italy. The product portfolio includes diverse therapeutic categories such as analgesics (Efferalganmed, Nurofen), antacids (Maalox), anti-inflammatory/anti-rheumatic medications (Daflon, Voltaren Emulgel), dermatological products (Daktarin, Pevaryl, Elocon), gastrointestinal medications (Imodium, Dulcolax, Enterogermina), antihistamines (Fexallegra), eye care products (Systane Ultra, Thealoz Duo, Optive Fusion, Recugel), cardiovascular medications, and other therapeutic agents. The company operates through its QUICKO online ordering platform for pharmacies and provides pharmacovigilance services for adverse reaction monitoring. Products are sourced from EU countries including France, UK, Germany, Spain, Portugal, Netherlands, Poland, Belgium, Hungary, Romania, Greece, Austria, Ireland, and others, relabeled and repackaged under AIFA authorization for the Italian market.

Differentiator

Problem solved

Functional benefit

Brands

• QUICKO: Online ordering platform for pharmacies providing rapid ordering, monthly billing, real-time product availability, order access with PDF download, and annual sales volume control.

Products and services

• Parallel Imported Pharmaceuticals Branded medications parallel-imported from EU member states (France, UK, Spain, Portugal, Germany, Netherlands, Poland, Belgium, Hungary, Austria, Greece, and others), authorized by AIFA through AIP (Autorizzazione di Importazione Parallela), relabeled and repackaged at authorized facilities, and distributed to Italian pharmacies. The portfolio spans more than 200 licensed products covering multiple therapeutic categories.
• QUICKO Online Ordering Platform Reserved-access online ordering platform exclusively for registered Italian pharmacies. Provides rapid order placement, monthly billing, real-time product availability, order history with PDF download, and annual sales-volume tracking for parallel-imported pharmaceutical products.
• Pharmacovigilance Services Drug safety monitoring service that collects, evaluates, and forwards adverse-reaction reports from healthcare professionals and patients to AIFA, EMA, and parent-group entities in line with EU pharmacovigilance obligations.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core.

• AIFA (Agenzia Italiana del Farmaco)coreOthersMedifarm's parallel imported products are authorized by AIFA (Italian Medicine Agency) through AIP (Autorizzazione di Importazione Parallela) for marketing throughout Italy.
• EMA (European Medicines Agency)coreOthersEuropean regulatory body overseeing pharmaceutical authorization and safety standards in the EU, referenced as part of Medifarm's regulatory compliance framework.
• MHRA (Medicines and Healthcare products Regulatory Agency)coreOthersBritish regulatory agency that controls the secondary repackaging operations of Medifarm's products sourced from the UK market.
• Bezirksregierung DüsseldorfcoreOthersGerman regulatory authority that oversees secondary repackaging operations for products sourced from Germany.
• Health and Youth Care Inspectorate - Pharmaceutical AffairscoreOthersRegulatory body that controls repackaging operations for products sourced from the Netherlands.
• European Multinational Group NetworkcoreStrategic or Co-development PartnerMedifarm is part of a European multinational group with offices in France, Great Britain, Spain, Portugal, Germany, and the Netherlands, enabling cross-border sourcing and operational synergies.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Orifarm Group: Orifarm is one of Europe's largest parallel importers of pharmaceuticals, headquartered in Denmark with broad coverage across EU markets. Like Medifarm, it sources branded drugs from lower-price member states and repackages them under local authorizations, making it the closest direct peer in business model, regulatory approach, and product mix.
• 2care4: 2care4 is a Denmark-based parallel importer and online pharmacy platform that distributes parallel-imported pharmaceuticals primarily in the Nordics. Its dual focus on parallel trade and digital pharmacy distribution closely parallels Medifarm's combination of parallel importation and the QUICKO online ordering platform.
• CC Pharma: CC Pharma is a German pharmaceutical wholesaler specializing in parallel imports and originator/innovator brands, supplying German pharmacies. Its parallel-import focus and sourcing model directly mirror Medifarm's Italian business, making it one of the most relevant country-level counterparts in the European parallel trade landscape.
• Paranova Group: Paranova is a Netherlands-based parallel importer and repackager of branded pharmaceuticals, distributing across multiple EU markets. Its model — sourcing cheaper SKUs from low-price member states and obtaining national authorizations for parallel import — mirrors Medifarm's Italian operations and makes it a highly comparable direct peer.
• Abcur AB: Abcur is a Swedish pharmaceutical company focused on parallel importation and repackaging of branded medicines for the Nordic market. It serves pharmacies with the same parallel-import arbitrage model as Medifarm, making it a direct competitor in concept and execution.

Emerging players

• Imres B.V. Imres is a Netherlands-based pharmaceutical wholesaler focused on supplying healthcare products to institutional and retail customers in emerging markets, including parallel-imported pharmaceuticals. Its parallel-import and repackaging overlap with Medifarm's operations makes it an adjacent comparable.

Broad incumbents

• AAH Pharmaceuticals: AAH is one of the UK's largest pharmaceutical wholesalers, supplying more than 6,000 pharmacies across the United Kingdom with branded, generic, and parallel-imported medicines. While predominantly a full-line distributor, its parallel-import operations directly overlap with Medifarm's business model and pharmacy-channel orientation.
• Phoenix Group: Phoenix Group is a leading European pharmaceutical distribution and retail group, operating in over 27 countries with a strong presence in pharmacy wholesale across Southern, Western, and Central Europe. Its pan-European wholesale footprint overlaps with Medifarm's pharmacy distribution model and gives it adjacent scale in regulated pharma distribution.
• Alliance Healthcare: Alliance Healthcare is one of the largest pharmaceutical wholesalers in Europe, distributing branded and generic medicines to pharmacies across multiple EU countries. While not a pure parallel importer, it operates parallel-import lines alongside its full-line wholesale business and serves overlapping pharmacy customers, making it a relevant broad incumbent peer.

Regional players

• Alloga UK: Alloga is a UK-based pharmaceutical distribution and pre-wholesale specialist, part of the Phoenix Group, with significant parallel-import and repackaging operations. It serves the UK and Ireland pharmacy channels via the same parallel-import and repackaging approach Medifarm uses in Italy, providing a meaningful same-business regional comparison.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medifarm-healthcare

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medifarm